S-1: Mustang Bio Seeks Up to $10.5 Million in New Offering to Fund Pipeline Development

Mustang Bio announces a proposed offering of common stock and warrants, or pre-funded warrants and warrants, aiming to raise capital for pipeline development and general corporate purposes.

Summary

• Mustang Bio, a clinical-stage biopharmaceutical company, is planning to offer up to shares of common stock and accompanying warrants, or pre-funded warrants and accompanying warrants.
• The company intends to use the net proceeds from this offering for working capital, pipeline development activities, and general corporate purposes.
• The offering includes warrants to purchase up to shares of common stock, with an exercise price to be determined, exercisable upon stockholder approval or immediately if certain pricing conditions are met, and expiring five years from the initial exercise date.
• Pre-funded warrants are also being offered to purchasers who would exceed beneficial ownership limits, exercisable for one share of common stock at $0.0001 per share.
• The combined offering price per share of common stock (or pre-funded warrant) and accompanying warrants will be fixed for the duration of this offering.
• The offering is being conducted on a best efforts basis with no minimum amount required to be sold.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol MBIO.
• As of March 14, 2024, the last reported sale price of Mustang Bio's common stock was $0.99 per share.
• The company has engaged a placement agent to assist with the offering and will pay fees including a cash fee equal to 7.0% of the gross proceeds raised in this offering and a management fee equal to 1.0% of the gross proceeds raised in this offering.

Sentiment

Score: 4

Explanation: The announcement of a capital raise is generally neutral, but the company's financial situation and the risks associated with the offering temper the sentiment.

Positives

• The offering aims to provide Mustang Bio with additional capital to advance its pipeline development activities.
• The company has multiple partnerships with world-class research institutions.
• The company has multiple ongoing Phase 1/2 clinical trials.

Negatives

• The offering is being made on a best efforts basis, and there is no guarantee that the company will raise the full amount it is seeking.
• The company has a history of operating losses and an accumulated deficit of $381.0 million as of December 31, 2023.
• The company's auditor included an explanatory paragraph in its audit report covering the December 31, 2023 financial statements that states the company's expectation to generate operating losses and negative operating cash flows in the future, and the need for additional funding to support its planned operations raise substantial doubt about its ability to continue as a going concern.
• There is no established public trading market for the warrants or the pre-funded warrants, and the company does not expect a market to develop.

Risks

• Investing in the company's securities involves risks, including potential dilution, market volatility, and the company's ability to effectively use the funds raised.
• The company's management has broad discretion over the use of the net proceeds from this offering and may use them in ways that may not enhance the company's operating results or the price of its common stock.
• The company's ability to continue as a going concern is dependent on raising additional funding.
• The company may be required to further revise its business plan and strategy, which may result in it further curtailing, delaying or discontinuing one or more of its research or development programs or the commercialization of any product candidates, selling certain of its assets and/or may result in it being unable to expand its operations or otherwise capitalize on its business opportunities.

Future Outlook

The company expects to receive FDA feedback in the first quarter of 2024 regarding its strategy to conduct a non-randomized registrational multicenter trial in relapsed or refractory WM and expects to treat the first patient in that trial in the second half of 2024, which could enable top-line results in the second half of 2026.

Industry Context

The company operates in the competitive biopharmaceutical industry, focused on cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.

Stakeholder Impact

• Shareholders will experience potential dilution as a result of the offering.
• Employees' jobs may be affected by the company's ability to secure funding and continue operations.
• The company's ability to develop and commercialize its product candidates will impact patients with hematologic cancers, solid tumors, and rare genetic diseases.
• The company's suppliers and creditors may be affected by its financial condition and ability to meet its obligations.

Next Steps

• The company intends to submit a Compliance Plan to Nasdaq on or before April 29, 2024.
• The company intends to promptly, and in no event later than 90 days after the consummation of this offering, seek stockholder approval for the issuance of shares of common stock issuable upon exercise of the warrants.
• The company expects to receive FDA feedback in the first quarter of 2024 regarding its strategy to conduct a non-randomized registrational multicenter trial in relapsed or refractory WM.
• The company expects to treat the first patient in the non-randomized registrational multicenter trial in relapsed or refractory WM in the second half of 2024.
• The company expects top-line results in the non-randomized registrational multicenter trial in relapsed or refractory WM in the second half of 2026.

Key Dates

Keywords

offering, common stock, warrants, pre-funded warrants, pipeline development, capital raise, MBIO, biopharmaceutical, clinical-stage, gene therapy, CAR T therapy